Agile Therapeutics, Inc.
Agile Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative contraceptive solutions for women. Founded in 2007, Agile has made significant strides in the women's health sector, particularly with its flagship product, Twirla, a transdermal contraceptive patch that offers a unique, convenient alternative to traditional birth control methods. With a commitment to addressing unmet needs in reproductive health, Agile Therapeutics has positioned itself as a leader in the industry, emphasising patient-centric solutions. The company operates primarily in the US market, where it continues to expand its reach and influence. Agile's dedication to research and development, coupled with its strategic partnerships, underscores its role as a key player in advancing women's health care.
DitchCarbon Score
How does Agile Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agile Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Agile Therapeutics, Inc.'s reported carbon emissions
Agile Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary and does not inherit emissions data from a parent organisation. Consequently, there are no documented reduction targets or climate pledges associated with Agile Therapeutics at this time. As a part of the broader industry context, many companies are increasingly committing to sustainability initiatives and setting science-based targets to reduce their carbon footprints. However, without specific data or commitments from Agile Therapeutics, it is unclear how they align with these industry standards. In summary, Agile Therapeutics, Inc. has not publicly disclosed any emissions data or climate commitments, reflecting a potential area for future development in their sustainability strategy.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Agile Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
